These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 18599600)

  • 1. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity.
    He G; Sung YM; Digiovanni J; Fischer SM
    Cancer Res; 2006 Feb; 66(3):1873-8. PubMed ID: 16452250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin.
    He G; Muga S; Thuillier P; Lubet RA; Fischer SM
    Mol Carcinog; 2005 Aug; 43(4):198-206. PubMed ID: 15864802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.
    Sánchez-Hidalgo M; Martín AR; Villegas I; de la Lastra CA
    Eur J Pharmacol; 2007 May; 562(3):247-58. PubMed ID: 17343846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts.
    Zhang GY; Cheng T; Zheng MH; Yi CG; Pan H; Li ZJ; Chen XL; Yu Q; Jiang LF; Zhou FY; Li XY; Yang JQ; Chu TG; Gao WY
    J Plast Reconstr Aesthet Surg; 2010 Jul; 63(7):1209-16. PubMed ID: 19617014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of multiple mitogen-activated protein kinases in pro/pre-B cells by GW7845, a peroxisome proliferator-activated receptor gamma agonist, and their contribution to GW7845-induced apoptosis.
    Schlezinger JJ; Emberley JK; Sherr DH
    Toxicol Sci; 2006 Aug; 92(2):433-44. PubMed ID: 16672323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
    Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth.
    Gouni-Berthold I; Berthold HK; Weber AA; Seul C; Vetter H; Sachinidis A
    Exp Clin Endocrinol Diabetes; 2001; 109(4):203-9. PubMed ID: 11453032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells.
    Yamakawa K; Hosoi M; Koyama H; Tanaka S; Fukumoto S; Morii H; Nishizawa Y
    Biochem Biophys Res Commun; 2000 May; 271(3):571-4. PubMed ID: 10814503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha.
    Yoon MJ; Lee GY; Chung JJ; Ahn YH; Hong SH; Kim JB
    Diabetes; 2006 Sep; 55(9):2562-70. PubMed ID: 16936205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
    Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
    Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone regulates c-reactive protein-induced inflammatory responses via glucocorticoid receptor-mediated inhibition of p38 mitogen-activated protein kinase-toll-like receptor 4 signal pathway in vascular smooth muscle cells.
    Liu N; Liu JT; Ji YY; Lu PP
    J Cardiovasc Pharmacol; 2011 Mar; 57(3):348-56. PubMed ID: 21383592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.
    Tencer L; Burgermeister E; Ebert MP; Liscovitch M
    Anticancer Res; 2008; 28(2A):895-906. PubMed ID: 18507034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
    Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
    Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
    Memon RA; Tecott LH; Nonogaki K; Beigneux A; Moser AH; Grunfeld C; Feingold KR
    Endocrinology; 2000 Nov; 141(11):4021-31. PubMed ID: 11089532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
    Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
    J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR gamma is an important transcription factor in 1 alpha,25-dihydroxyvitamin D3-induced involucrin expression.
    Dai X; Sayama K; Shirakata Y; Tokumaru S; Yang L; Tohyama M; Hirakawa S; Hanakawa Y; Hashimoto K
    J Dermatol Sci; 2008 Apr; 50(1):53-60. PubMed ID: 18077140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.